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Abstract: The study’s purpose was to determine the incidence, risk factors, and outcomes of
tractional macular detachment after anti-vascular endothelial growth factor (VEGF) pretreatment
before vitrectomy for complicated proliferative diabetic retinopathy. Patients who underwent primary
vitrectomy for complicated proliferative diabetic retinopathy, from January 2012 to 31 December 2018,
were enrolled. Ophthalmic and pre-operative data were extracted from electronic record systems.
All eyes with a valuable Optical Coherence Tomography (OCT)performed within 5 days before
injection of anti-VEGF and on the day of vitrectomy were included. Multivariable logistic regression
showed that significant risk factors for developing tractional macular detachment included days
between anti-VEGF and vitrectomy (OR, 0.71 [95% CI 0.65–0.76]; p < 0.001), vitreous hemorrhage
(OR, 0.23 [95% CI 0.11–0.49]; p < 0.001), and age (OR, 1.05 [95% CI 1.02–1.08]; p < 0.001). Decision-tree
analysis showed that the stronger predictors of tractional macular detachment were the time between
anti-VEGF injection and vitrectomy (p < 0.001). Secondary predictors were the presence of vitreous
hemorrhage (p = 0.012) in eyes that underwent vitrectomy between 6 and 10 days after anti-VEGF
injection and younger age (p = 0.031) in eyes that underwent vitrectomy 10 days after anti-VEGF
injection. Tractional macular detachment occurs in 10% of eyes after anti-VEGF injection, the main
risk factors being days between anti-VEGF injection and vitrectomy, vitreous hemorrhage, and age.
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1. Introduction
Diabetic retinopathy (DR) is the leading cause of visual loss in working-age adults in developed
countries [1]. In some studies that reported incidence in Italy, the cumulative incidence of DR
ranged from 34% to 59% during a four-year period, depending on the age of patient and severity of
disease [2,3]. Proliferative diabetic retinopathy (PDR) is the worst stage of DR, and is characterized by
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the development of retinal neovascularization, which usually leads to serum leakage, hemorrhage, and
fibrovascular proliferation in the vitreous–retinal interface. Fibrosis and neovascularization ultimately
lead to vision loss due to tractional retinal detachment (TRD) in untreated eyes [4].
Pars plana vitrectomy is broadly considered the gold standard for management of this condition;
however, the occurrence of intra-operative hemorrhage when dissecting the epiretinal neovascular
membrane can reduce the outcome of surgery both anatomically and functionally. Reiterated bleeding
can also prolong operation time and significantly increase the rate of complications [5,6].
The pathophysiological basis of PDR is angiogenesis [7]. Vascular endothelial growth factor
(VEGF) has been confirmed to be a crucial driver of vascular permeability, diabetic macular edema,
neovascularization and PDR [8–10].
Intra-vitreal administration of anti-vascular endothelial growth factor (anti-VEGF) is variably
used as an addition to vitrectomy to improve the outcome of surgery by reducing the incidence of
intra-operative and post-operative vitreous hemorrhage and to ease the delamination of fibrovascular
membranes [11–13].
Intra-vitreal injections of anti-VEGF in adjunct to vitrectomy can therefore determine better visual
acuity, fewer retinal breaks, fewer endo-diathermy applications, decrease the duration of surgery, and
intra-operative bleeding [13–17].
On the other hand, intra-vitreal anti-VEGF has been proved to be able to increase the severity of
fibrosis with progression or development of TRD shortly after injection in patients affected by PDR.
Similarly, a fibrotic switch has been shown in diabetic fibrovascular proliferative membranes after
bevacizumab [18–20].
The purpose of this retrospective study was to evaluate the incidence and risk factors of tractional
macular detachment (TMD) following intra-vitreal anti-VEGF pretreatment before vitrectomy for
complicated PDR.
2. Materials and Methods
In this retrospective multicenter cohort study, we included all consecutive patients who had
undergone primary pars plana vitrectomy for TRD, fibrous proliferation, or a combination of these,
related to active PDR after anti-VEGF pretreatment, from January 2012 to 31 December 2018, at 4 tertiary
vitreoretinal centers in Italy: the Eye Clinic of the University of Catania; the Eye Clinic of the University
of Sassari; the Eye Clinic of the University of Bari; and the Eye Clinic of the University of Palermo.
Anti-VEGF is indicated for the treatment of patients with diabetic macular edema. The “off-label”
status of this medication for PDR, and possible systemic and ocular complications, was discussed in
detail, and informed consent was obtained from all patients. The study protocol, approved by the
institutional review boards of the coordinating center (University of Catania, Catania, Italy, Ethical
code 39/724/2011/pol) and the other participating centers, conformed to the tenets of the Declaration
of Helsinki.
Inclusion criteria for the use of intra-vitreal anti-VEGF before vitrectomy for the management
of PDR included active proliferative diabetic retinopathy, TRD not involving the macula, fibrous
proliferation, or a combination of these with associated reduced visual acuity.
Exclusion criteria consisted of dense vitreous hemorrhage preventing visualization of the posterior
pole preoperatively and grading of fibrovascular membranes, eyes that had undergone any previous
ocular surgery, except uncomplicated cataract surgery, a history of ocular inflammatory disease,
patients with other intraocular diseases that may have affected the vitreoretinal surgery, such as retinal
vascular disorders, traumatic retinal detachment, uveitis, and congenital vitreoretinopathies, and
patients who had undergone any previous intra-vitreal anti-VEGF injections in the previous 6 months.
All patients were divided into two groups according to the presence or not of TMD on the day of
vitrectomy. Patients were considered to have a TMD when preretinal membranes exerted traction on
the retina resulting in the presence of sub-macular fluid on Spectral-Domain OCT (SD-OCT). Patients
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were considered to have fibrovascular proliferation when preretinal membranes exerted traction on
the retina with or without intraretinal edema but without subretinal fluid on SD-OCT [21].
Only eyes with a valuable OCT performed within 5 days before injection of anti-VEGF and on
the day of vitrectomy were included. The interval between anti-VEGF injection and vitrectomy was
also assessed.
Only 1 eye of each subject was permitted into the study. If both eyes of 1 patient qualified for
enrollment, the most affected eye was selected for the study [21].
Patient demographics, complete medical and ophthalmic history, the most recent hemoglobin A1c
level, years affected by diabetes, ophthalmic data including phackic/pseudophakic condition, and laser
photocoagulation partial/panphotocoagulation before anti-VEGF injection were drawn from electronic
medical records.
In each center, 2 separate investigators qualified in the methods of chart abstraction were committed
to the task of reviewing the charts of patients separately. Definitions for key variables and all data
abstraction forms were reviewed. Chart abstractors were blinded regarding the aim of the study.
Statistical Analysis
The total number of anti-VEGF injections and vitrectomy procedures was identified, and the
overall incidence rate of TMD was calculated. Using the chi-square or Fisher exact tests for categorical
variables, and Mann–Whitney tests for quantitative variables, potential risk factors for TMD were
identified in univariate analyses. Odds ratio was also calculated; for the continuous variables, Exp(B)
from binary logistic regression was used. Risk factors that were significant at the p = 0.2 level, and the
univariate analysis was included in the multivariable logistic regression analysis.
We also investigated the predicting capability of variables using a regression based on conditional
inference decision trees. Risk models were developed using a decision-tree induction from class labeled
training records: the development of TMD was the dependent variable, and the other attributes were
the predictor variables; the individual records are the tuples for which the class label is known, as
previously described [22].
All differences were considered to be statistically significant at a 5% probability level, and all
reported p values are 2-sided. Statistical analysis used IBM SPSS Statistics for Windows (Version 21.0;
IBM Corp, Armonk, NY, USA)
3. Results
The recruitment flowchart is shown in Figure 1.
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Overall, charts from 1011 eyes that had anti-VEGF injection before vitrectomy at 4 surgical units
between January 2012 and December 2018 were reviewed. 608 eyes were included in the analysis.
The mean ± SD age was 48.7 ± 10.8 years in patients who developed TMD after anti-VEGF
injection and 54.8 ± 10.9 years in patients who did not develop TMD after anti-VEGF injection. There
were 33/(n = 61) (54.1%) male patients who developed TMD after anti-VEGF injection and 279/(n = 547)
(51%) male patients who did not develop TMD after anti-VEGF injection.
3.1. TMD Incidence
Overall, the incidence of TMD after anti-VEGF was 10%, 61/608 in the eyes that had anti-VEGF
before vitrectomy (chi-square; p < 0.001).
3.2. Univariate Analysis
Univariate analysis showed that significant variables related with increased risk of TMD included:
younger age (48.7 ± 10.8 years in eyes that developed TMD after anti-VEGF, 54.8 ± 10.9 years in in eyes
which did not develop TMD; odds ratio [OR], 0.95 [95% CI 0.93–0.97]; p < 0.001), higher HbA1c, (7.9 ±
0.7% in eyes that developed TMD, 7.7 ± 0.4% in in eyes that did not develop TMD; OR, 2.12 [95% CI
1.27–3.53]; p = 0.004), days between anti-VEGF and vitrectomy (11.8 ± 6.1 days in eyes that developed
TMD after anti-VEGF, 5.7 ± 2.7 days in in eyes that did not develop TMD after anti-VEGF; odds ratio
[OR], 1.40 [95% CI 1.30–1.52]; p < 0.001) (Table 1).
Table 1. Univariate Analysis of Variables in eyes with and without tractional macular detachment








p Value OR (95% CI)
Age, mean ± SD (years) 48.7 ± 10.8 54.8 ± 10.9 <0.001 a 0.95 (0.93–0.97)
Males, n (%) 33 (54.1) 279 (51.0) 0.686 1.13 (0.67–1.92)
Diabetes type 1, n (%) 4 (6.6) 26 (4.8) 0.758 0.71 (0.24–2.11)
HbA1c, (%) 7.9 ± 0.7 7.7 ± 0.4 0.004 a 2.12 (1.27–3.53)
Length of diabetes, (years) 16.3 ± 4.9 16.3 ± 3.4 0.969 0.99 (0.94–1.06)
Pseudophakic/aphakic, n (%) 18 (33.8) 194 (35.0) 0.397 0.76 (0.43–1.36)
Vitreous hemorrhage 44 (72.1) 301 (55.0) 0.014 a 2.12 (1.18–3.80)
Localized photocoagulation, n (%) 51 (86.6) 385 (70.4) 0.035 a 2.14 (1.06–4.33)
Extensive photocoagulation, n (%) 10 (16.4) 162 (29.6) 0.035 a 0.47 (0.23–0.94)
Days between anti-VEGF
and vitrectomy 11.8 ± 6.1 5.7 ± 2.7 <0.001
a 1.40 (1.30–1.52)
SD = standard deviation; OR = odds ratio; CI = confidence interval; IOL = intraocular lens; a Statistically significant.
3.3. Multivariable Analysis
Significant variables at univariate analysis were taken forward to multivariable analysis. A
regression model was constructed for the risk of developing TMD after anti-VEGF injection. Significant
risk factors for developing TMD included days between anti-VEGF and vitrectomy (OR, 0.71 [95% CI
0.65–0.76]; p < 0.001), vitreous hemorrhage (OR, 0.23 [95% CI 0.11–0.49]; p < 0.001), and younger age
(OR, 1.05 [95% CI 1.02–1.08]; p < 0.001) (Table 2).
Table 2. Independently significant risk factors for developing tractional macular detachment detected
at OCT after anti-VEGF intra-vitreal injection in the multivariate logistic regression.
Variables OR (95% CI) p Value
Days between anti-VEGF and vitrectomy 0.71 0.65–0.76 <0.001
Vitreous Hemorrhage 0.23 0.11–0.49 <0.001
Age 1.05 1.02–1.08 0.001
OR = odds ratio; CI = confidence interval.
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3.4. Decision-Tree Analysis
The outcome of the decision-tree analysis for the prediction of TMD is shown in Figure 2.
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4. Discussion
A challenging condition faced by vitreoretinal surgeons is the surgical management of PDR
complications. The m st reported post-operativ complication after vitrectomy is vitreous hem rrhage,
reaching 75% in some studies when pre- perative anti-VEGF w s not dministered [23–26].
Neovascul rization, secondary o PDR, can effectively be reduced [27,28], nd surgical
visualization can be improved by pre-operative anti-VEGF, which were shown to reduce intra-operative
hemorrhaging and facilitat fibrovascular membrane delamination resulting in a lower incidence of
iatrogenic breaks [17,19,20,27,29,30].
However, development or progression of TRD soon after pre-operative anti-VEGF injection may
occur in as many as 5.2% of cases [31].
Vitrectomy should therefore be performed after sufficient time has passed to allow regression of
neovascularization but before fibrovascular contraction.
Some studies have reported regression of neovascularization during the first week after treatment
with intra-vitreal bevacizumab in PDR patients [14,32]. In patients affected by PDR who had anti-VEGF
at various intervals before Pars Plana Vitrectomy (PPV), El-Sabagh and associates [30] analyzed
different components of proliferative fibrovascular membranes (collagen, CD34, and smooth muscle
actin). The vascular component of proliferation was significantly reduced 10 days after intra-vitreal
bevacizumab injection, whereas the contractile components were not abundant; therefore, 10 days might
be considered the ideal timing for pre-operative intra-vitreal bevacizumab injection. They also showed
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that pan-endothelial marker CD34, expressed significantly in neovascular vessels, was not significantly
reduced until 5 days after intra-vitreal bevacizumab injection, suggesting that pre-operative intra-vitreal
bevacizumab administered before 5 days may not provide enough time for neovascular regression.
Van Geest and associates [33] showed that connective tissue growth factor (CTGF) levels were
highly correlated with the degree of vitreoretinal fibrosis in PDR. Furthermore, they established that the
CTGF/VEGF ratio was the highest predictor of fibrosis in PDR patients and that intra-vitreal anti-VEGF
treatment determined augmented fibrosis in PDR patients [33].
Wei and associates [34] showed that the fibrin–fibronectin complex is the key factor that directly
promotes the progression of fibrosis, while CTGF increases fibrosis by enhancing the affinity of
fibronectin to fibrin in pathologic conditions. They suggested that fibrin–fibronectin complex formation
is a molecular mechanism underlying the development of TRD after intra-vitreal anti-VEGF injection.
Our results show that the presence of vitreous hemorrhage increases the risk of TRD, therefore it is
conceivable that the risk increases with copious vitreous hemorrhage. This might explain why, in our
study, the patients diagnosed with dense vitreous hemorrhage were more likely to develop severe
TRD after intra-vitreal anti-VEGF injection.
Castillo and associates [21] compared two different pre-operative intra-vitreal bevacizumab
treatment intervals in PDR patients undergoing PPV. Pre-operative intra-vitreal bevacizumab performed
5–10 days before PPV produced a significantly better best corrected visual acuity (BCVA) and fewer
post-operative complications at 6 months compared to pre-operative intra-vitreal bevacizumab
performed 1–3 days before, principally in cases with worse vitreoretinal adhesion and when the
indication for surgery was fibrous proliferation, TRD, or a combination of fibrous proliferation, vitreous
hemorrhaging, and TRD. Their results suggest that pre-operative intra-vitreal bevacizumab performed
1–3 days before PPV may not allow enough time to effectively regress neovascularization, compared to
intra-vitreal bevacizumab performed 5–10 days before PPV [21].
Previous studies reported a pre-operative injection of intra-vitreal bevacizumab from 1 to 33 days
before PPV for PDR-related complications [11,14,15,17,19,20,29,30,35,36] and TRD incidence between
5.2% [31] and 9% [37].
The results of our study, performed on over 600 eyes, identified less than 6 days as a safe period
to perform PPV following anti-VEGF and an incidence rate of TMD after anti-VEGF of 10%. The
possible differences are due to the different inclusion criteria that have been used in various studies.
Furthermore, in our study, we evaluated the presence of TMD with OCT examination to have a more
sensitive evaluation than just the examination of the fundus.
In our study, multivariate analysis showed that 3 factors had a significant effect on the incidence:
days between anti-VEGF and vitrectomy, vitreous hemorrhage, and age. We used a decision-tree
analysis to analyze the interactions and priorities among them; this is a modeling procedure that
has several advantages, including automatically capturing multilevel interactions among predictors,
handling nonlinear relationships, rule generation, and ease of visualization and interpretation [38]. In
addition, a decision-tree model can be successfully used in clinical settings since the primary related
factors can be identified [39].
The decision-tree model identified the time between anti-VEGF injection and vitrectomy as the
main variable associated with TMD.
In eyes where vitrectomy was performed within 6 days of anti-VEGF injection, the risk of
developing TMD was extremely low, regardless of other variables. TMD developed in 12% of patients
who received vitrectomy between 6 and 10 days after anti-VEGF injection; in this group, the risk
significantly increased if there was a vitreous hemorrhage associated with Proliferative Diabetic
Retinopathy (PDR). Finally, in the eyes where vitrectomy was performed more than 10 days after
anti-VEGF, the risk of developing TMD was very high (over half of the eyes), particularly in patients
with a younger age. Therefore, it can be useful to perform surgery within 10 days from anti-VEGF
injection or within 6 days in the presence of vitreous hemorrhage.
J. Clin. Med. 2019, 8, 1960 7 of 9
This study has some limitations. First, some bias in the identification of variables might be
introduced by the retrospective nature of the study; however, to minimize bias, a rigorous protocol of
data extraction was defined at the study planning stage for all variables. Another limitation of the
study is that eyes that had vitreous hemorrhages not allowing the exploration of the fundus were
excluded. Furthermore, our results do not necessarily apply to the general population, as they were
found in 4 Italian tertiary facilities and we did not evaluate association of the treatment outcome on
the type or class of antidiabetics that the patients were taking to keep their diabetes under control.
In conclusion, TMD occurs in 10% of eyes after anti-VEGF injection, the main risk factors being
days between anti-VEGF injection and vitrectomy, vitreous hemorrhage, and age.
Further prospective studies are needed to evaluate the efficacy of potential strategies in the
prevention of TMD.
Author Contributions: Conceptualization, T.A. and M.R.; Data curation, A.L., M.F., R.R. and K.N.; Formal
analysis, A.L.; Investigation, A.R., V.B., F.B., C.F. and S.C.; Visualization, M.T.; Writing – original draft, A.R.
Funding: This research received no external funding.
Acknowledgments: We wish to thank Dott. A. Bridgewood of the Scientific Bureau of the University of Catania
for language support.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Eliott, D.; Lee, M.S.; Abrams, G.W. Proliferative diabetic retinopathy: Principles and techniques of surgical
treatment. In Retina, 4th ed.; Ryan, S.J., Ed.; Elsevier Mosby: St Louis, MO, USA, 2006; pp. 2413–2449.
2. Segato, T.; Midena, E.; Grigoletto, F.; Zucchetto, M.; Fedele, D.; Piermarocchi, S.; Crepaldi, G. Veneto Group
for Diabetic Retinopathy. The epidemiology and prevalence of diabetic retinopathy in the Veneto region of
North East Italy. Diabet. Med. 1991, 8, S11–S16. [CrossRef] [PubMed]
3. Porta, M.; Tomalino, M.G.; Santoro, F.; Ghigo, L.D.; Cairo, M.; Aimone, M.; Pietragalla, G.B.; Passera, P.;
Montanaro, M.; Molinatti, G.M. Diabetic retinopathy as a cause of blindness in the province of Turin,
North-west Italy, in 1967–1991. Diabet. Med. 1995, 12, 355–361. [CrossRef] [PubMed]
4. Rice, T.A.; Michels, R.G.; Rice, E.F. Vitrectomy for Diabetic Traction Retinal Detachment Involving the Macula.
Am. J. Ophthalmol. 1983, 95, 22–33. [CrossRef]
5. Schrey, S.; Krepler, K.; Wedrich, A. Incidence of rhegmatogenous retinal detachment after vitrectomy in eyes
of diabetic patients. Retina 2006, 26, 149–152. [CrossRef] [PubMed]
6. Hershberger, V.S.; Augsburger, J.J.; Hutchins, R.K.; Raymond, L.A.; Krug, S. Fibrovascular ingrowth
at sclerotomy sites in vitrectomized diabetic eyes with recurrent vitreous hemorrhage: Ultrasound
biomicroscopy findings. Ophthalmology 2004, 111, 1215–1221. [CrossRef]
7. Shi, L.; Huang, Y.-F. Postvitrectomy diabetic vitreous hemorrhage in proliferative diabetic retinopathy. J. Res.
Med. Sci. 2012, 17, 865–871.
8. Blum, A.; Socea, D.; Ben-Shushan, R.S.; Keinan-Boker, L.; Naftali, M.; Segol, G.; Tamir, S. A decrease in VEGF
and inflammatory markers is associated with diabetic proliferative retinopathy. Eur. Cytokine Netw. 2012, 23,
158–162. [CrossRef]
9. Morera, Y.; González, R.; Lamdan, H.; Pérez, L.; González, Y.; Agüero, J.; Castro, J.; Romero, J.C.;
Etchegoyen, A.Y.; Ayala, M.; et al. Vaccination with a mutated variant of human Vascular Endothelial Growth
Factor (VEGF) blocks VEGF-induced retinal neovascularization in a rabbit experimental model. Exp. Eye Res.
2014, 122, 102–109. [CrossRef]
10. Wisniewska-Kruk, J.; Klaassen, I.; Vogels, I.M.; Magno, A.L.; Lai, C.M.; Van Noorden, C.J.; Schlingemann, R.O.;
Rakoczy, E.P. Molecular analysis of blood-retinal barrier loss in the Akimba mouse, a model of advanced
diabetic retinopathy. Exp. Eye Res. 2014, 122, 123–131. [CrossRef]
11. Smith, J.M.; Steel, D.H.W. Anti-vascular endothelial growth factor for prevention of postoperative vitreous
cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst. Rev. 2015,
2015, CD008214. [CrossRef]
J. Clin. Med. 2019, 8, 1960 8 of 9
12. Pakzad-Vaezi, K.; Albiani, D.A.; Kirker, A.W.; Merkur, A.B.; Kertes, P.J.; Eng, K.T.; Fallah, N.; Forooghian, F.
A Randomized Study Comparing the Efficacy of Bevacizumab and Ranibizumab as Pre-treatment for Pars
Plana Vitrectomy in Proliferative Diabetic Retinopathy. Ophthalmic Surg. Lasers Imaging Retin. 2014, 45,
521–524. [CrossRef] [PubMed]
13. Simunovic, M.P.; Maberley, D.A. Anti-vascular endothelial growth factor therapy for proliferative diabetic
retinopathy: A systematic review and meta-analysis. Retina 2015, 35, 1931–1942. [CrossRef] [PubMed]
14. Zhang, Z.-H.; Liu, H.-Y.; Mota, S.E.H.-D.; Romano, M.R.; Falavarjani, K.G.; Ahmadieh, H.; Xu, X.; Liu, K.
Vitrectomy With or Without Preoperative Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy: A
Meta-Analysis of Randomized Controlled Trials. Am. J. Ophthalmol. 2013, 156, 106–115. [CrossRef] [PubMed]
15. Zhao, L.-Q.; Zhu, H.; Zhao, P.-Q.; Hu, Y.-Q. A systematic review and meta-analysis of clinical outcomes of
vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br. J.
Ophthalmol. 2011, 95, 1216–1222. [CrossRef] [PubMed]
16. Su, L.; Ren, X.; Wei, H.; Zhao, L.; Zhang, X.; Liu, J.; Su, C.; Tan, L.; Li, X. Intravitreal Conbercept (Kh902) for
Surgical Treatment of Severe Proliferative Diabetic Retinopathy. Retina 2016, 36, 938–943. [CrossRef]
17. Hernández-Da Mota, S.E.; Nuñez-Solorio, S.M. Experience with intravitreal bevacizumab as a preoperative
adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy. Eur. J. Ophthalmol. 2010, 20,
1047–1052. [CrossRef]
18. Comyn, O.; Wickham, L.; Charteris, D.G.; Sullivan, P.M.; Ezra, E.; Gregor, Z.; Aylward, G.W.; da Cruz, L.;
Fabinyi, D.; Peto, T.; et al. Ranibizumab pretreatment in diabetic vitrectomy: A pilot randomised controlled
trial (the RaDiVit study). Eye 2017, 31, 1253–1258. [CrossRef]
19. Farahvash, M.S.; Majidi, A.R.; Roohipoor, R.; Ghassemi, F. Preoperative injection of intravitreal bevacizumab
in dense diabetic vitreous hemorrhage. Retina 2011, 31, 1254–1260. [CrossRef]
20. Ahn, J.; Woo, S.J.; Chung, H.; Park, K.H. The Effect of Adjunctive Intravitreal Bevacizumab for Preventing
Postvitrectomy Hemorrhage in Proliferative Diabetic Retinopathy. Ophthalmology 2011, 118, 2218–2226.
[CrossRef]
21. Castillo, J.; Aleman, I.; Rush, S.W.; Rush, R.B. Preoperative Bevacizumab Administration in Proliferative
Diabetic Retinopathy Patients Undergoing Vitrectomy: A Randomized and Controlled Trial Comparing
Interval Variation. Am. J. Ophthalmol. 2017, 183, 1–10. [CrossRef]
22. Reibaldi, M.; Longo, A.; Pulvirenti, A.; Avitabile, T.; Russo, A.; Cillino, S.; Mariotti, C.; Casuccio, A.
Geo-Epidemiology of Age-Related Macular Degeneration: New Clues Into the Pathogenesis. Am. J.
Ophthalmol. 2016, 161, 78–93.e1-2. [CrossRef] [PubMed]
23. Oyakawa, R.T.; Schachat, A.P.; Michels, R.G.; Rice, T.A. Complications of vitreous surgery for diabetic
retinopathy. (I. Postoperative complications). Ophthalmology 1983, 90, 517–521. [CrossRef]
24. Schachat, A.P.; Oyakawa, R.T.; Michels, R.G.; Rice, T.A. Complications of vitreous surgery for diabetic
retinopathy (II. Postoperative complications). Ophthalmology 1983, 90, 522–530. [CrossRef]
25. Tolentino, F.I.; Cajita, V.N.; Gancayco, T.; Skates, S. Vitreous hemorrhage after closed vitrectomy for
proliferative diabetic retinopathy. Ophthalmology 1989, 96, 1495–1500. [CrossRef]
26. Novak, M.A.; Rice, T.A.; Michels, R.G.; Auer, C. Vitreous hemorrhage after vitrectomy for diabetic retinopathy.
Ophthalmology 1984, 91, 1485–1489. [CrossRef]
27. Spaide, R.F.; Fisher, Y.L. Intravitreal bevacizumab treatment of proliferative diabetic retinopathy complicated
by vitreous hemorrhage. Retina 2006, 26, 275–278. [CrossRef]
28. Avery, R.L.; Pearlman, J.; Pieramici, D.J.; Rabena, M.D.; Castellarin, A.A.; Nasir, M.A.; Giust, M.J.; Wendel, R.;
Patel, A. Intravitreal bevacizumab in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006,
113, 1695–1705. [CrossRef]
29. Chen, E.; Park, C.H. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment
repair in severe proliferative diabetic retinopathy. Retina 2006, 26, 699–700. [CrossRef]
30. El-Sabagh, H.A.; Abdelghaffar, W.; Labib, A.M.; Mateo, C.; Hashem, T.M.; Al-Tamimi, D.M.; Selim, A.A.
Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: Histopathologic findings
and clinical implications. Ophthalmology 2011, 118, 636–641. [CrossRef]
31. Arevalo, J.F.; Maia, M.; Flynn HWJr Saravia, M.; Avery, R.L.; Wu, L.; Eid Farah, M.; Pieramici, D.J.;
Berrocal, M.H.; Sanchez, J.G. Tractional retinal detachment following intravitreal bevacizumab in patients
with severe proliferative diabetic retinopathy. Br. J. Ophthalmol. 2008, 92, 213–216. [CrossRef]
J. Clin. Med. 2019, 8, 1960 9 of 9
32. Jorge, R.; Costa, R.A.; Calucci, D.; Cintra, L.P.; Scott, I.U. Intravitreal bevacizumab for persistent new vessels
in diabetic retinopathy. Retina 2006, 26, 1006–1013. [CrossRef] [PubMed]
33. Van Geest, R.J.; Lesnik-Oberstein, S.Y.; Tan, H.S.; Mura, M.; Goldschmeding, R.; Van Noorden, C.J.; Klaassen, I.;
Schlingemann, R.O. A shift in the balance of vascular endothelial growth factor and connective tissue growth
factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br. J. Ophthalmol.
2012, 96, 587–590. [CrossRef] [PubMed]
34. Wei, Q.; Zhang, T.; Jiang, R.; Chang, Q.; Zhang, Y.; Huang, X.; Gao, X.; Jin, H.; Xu, G. Vitreous Fibronectin
and Fibrinogen Expression Increased in Eyes With Proliferative Diabetic Retinopathy After Intravitreal
Anti-VEGF Therapy. Investig. Ophthalmol. Vis. Sci. 2017, 58, 5783–5791. [CrossRef] [PubMed]
35. Ahmadieh, H.; Shoeibi, N.; Entezari, M.; Monshizadeh, R. Intravitreal bevacizumab for prevention of early
postvitrectomy hemorrhage in diabetic patients: A randomized clinical trial. Ophthalmology 2009, 116,
1943–1948. [CrossRef] [PubMed]
36. Ishikawa, K.; Honda, S.; Tsukahara, Y.; Negi, A. Preferable use of intravitreal bevacizumab as a pretreatment
of vitrectomy for severe proliferative diabetic retinopathy. Eye (Lond) 2009, 23, 108–111. [CrossRef]
37. Oshima, Y.; Shima, C.; Wakabayashi, T.; Kusaka, S.; Shiraga, F.; Ohji, M.; Tano, Y. Microincision vitrectomy
surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment.
Ophthalmology 2009, 116, 927–938. [CrossRef]
38. Reibaldi, M.; Longo, A.; Romano, M.R.; Cennamo, G.; Mariotti, C.; Boscia, F.; Bonfiglio, V.; Avitabile, T.
Delayed suprachoroidal hemorrhage after pars plana vitrectomy: 5-year results of a retrospective multicenter
cohort study. Am. J. Ophthalmol. 2015, 160, 1235–1242. [CrossRef]
39. Piper, M.E.; Loh, W.Y.; Smith, S.S.; Japuntich, S.J.; Baker, T.B. Using decision tree analysis to identify risk
factors for relapse to smoking. Subst. Use Misuse 2011, 46, 492–510. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
